Related Experiment Video

Updated: Apr 21, 2026

Phospholipid Mediator Induced Transformation in Three-Dimensional Cultures
08:02

Phospholipid Mediator Induced Transformation in Three-Dimensional Cultures

Published on: July 27, 2022

3.0K

Targeting platelet-derived growth factor (PDGF) signaling in gastrointestinal cancers: preclinical and clinical

Omar Abdel-Rahman1

  • 1Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt, omar.abdelrhman@med.asu.edu.eg.

Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
|November 15, 2014
PubMed

Insights

Targeted therapies for advanced gastrointestinal cancers show promise. This review focuses on platelet-derived growth factor (PDGF) pathway inhibitors, exploring their biological and clinical use in GI cancers.

Area of Science:

  • Oncology
  • Gastroenterology
  • Molecular Biology

Background:

  • Advanced gastrointestinal malignancies have a poor prognosis, necessitating novel therapeutic strategies.
  • Targeted therapies are emerging, focusing on key signaling pathways driving tumor growth and metastasis.
  • Platelet-derived growth factor (PDGF) is implicated in gastrointestinal cancer progression.

Purpose of the Study:

  • To review the biological and clinical aspects of PDGF pathway-targeted therapies in gastrointestinal cancers.
  • To highlight the potential and future directions of PDGF inhibition in treating GI malignancies.

Main Methods:

  • Literature review of biological mechanisms of PDGF signaling in GI cancers.
  • Analysis of clinical trial data and outcomes for PDGF-targeted therapies.
  • Discussion of emerging trends and future research avenues.

Main Results:

  • PDGF signaling pathways play a crucial role in gastrointestinal tumor progression and metastasis.
  • Several targeted agents inhibiting the PDGF pathway have been developed.
  • Early clinical data suggest potential efficacy, but further research is needed.

Conclusions:

  • PDGF pathway-targeted therapies represent a promising avenue for personalized treatment of gastrointestinal cancers.
  • Further investigation into optimal patient selection and combination strategies is warranted.
  • The future of GI cancer treatment may involve tailored therapies targeting specific molecular pathways like PDGF.

More Related Videos

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

14.9K
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.7K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.2K
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
3.9K
Role Of Notch Signalling In Intestinal Stem Cell Renewal01:12

Role Of Notch Signalling In Intestinal Stem Cell Renewal

Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
2.6K
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
4.5K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
11.1K